Rapid translation of basic information in cutaneous biology to preclinical studies and clinical practice is becoming a realistic prospect due to the ever-increasing sophistication of basic research on development, regeneration, immunology, and diseases of the skin, together with powerful new technologies for gathering and analyzing genome-wide and population-based data. The overall goals of the proposed Penn SBDRC are to leverage our strengths in basic and translational science and dermatoepidemiology to support outstanding basic research in cutaneous biology and diseases and to promote the critical transition from bench research to bedside practice. To achieve these goals we will establish Resource and Administrative Cores. The Resource Cores are designed to enable and enhance the speed and efficiency of skin research; provide unique expertise and access to cutaneous tissues and specialized reagents; provide guidance on appropriate study design; provide easy access to biostatistical and bioinformatics support personnel; and continuously innovate to maintain our research at the forefront of the field. They are: Core A - Skin Histology and Characterization; Core B - Skin Procurement and Engineering; and Core C - Study Design and Data Analysis.
The aims of the Administrative Core are to: provide structure and oversight for the SBDRC; ensure the diversity and success of researchers in cutaneous biology and diseases; attract new investigators to cutaneous research; and foster exchange of ideas, collaboration, and interdisciplinary and basic-translational projects. To achieve these Aims, the Administrative Core will: (i) establish an Executive Committee to provide financial management and oversight; (ii) organize an Advisory Committee of internal and external experts to provide feedback and suggest improvements, and a Diversity Advisory Committee to advise the Executive Committee on strategies to ensure diversity through best hiring and retention practices; (iii) provide administrative support to the SBDRC and Core Directors; (iv) organize specific mentoring programs for junior faculty, senior trainees, women and diversity faculty and trainees, and Core Directors; (v) organize monthly Peer Mentoring research presentations/grant application discussions; (vi) establish a Community Outreach Program to attract students from the predominantly minority Philadelphia school district to the excitement and promise of cutaneous research; (vii) provide Pilot & Feasibility Studies funding to support young investigators, interdisciplinary and/or basic-translational collaborations, and investigators from outside Dermatology interested in skin-oriented research; (viii) sponsor Seminars related to cutaneous biology and disease; (ix) hold an Annual Research Retreat; (x) organize Communications functions including a quarterly newsletter and an SBDRC website to advertise SBDRC seminars and meetings, Core services, and membership information.

Public Health Relevance

Rapid translation of basic information in skin biology to preclinical studies and clinical practice is becoming a realistic prospect due to the ever-increasing sophistication of basic research on development, regeneration, immunology, and diseases of the skin, together with powerful new technologies for gathering and analyzing genome-wide and population-based data. The overall goal of the proposed Penn SBDRC is to leverage our strengths in basic and translational science and dermatoepidemiology to promote the critical transition from bench research to bedside practice, for the benefit of patients suffering from both common and rare cutaneous diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
1P30AR069589-01
Application #
9086672
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Program Officer
Baker, Carl
Project Start
2016-09-15
Project End
2021-08-31
Budget Start
2016-09-15
Budget End
2017-08-31
Support Year
1
Fiscal Year
2016
Total Cost
$805,000
Indirect Cost
$305,000
Name
University of Pennsylvania
Department
Dermatology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Shaw, Lauren; Mansfield, Corrine; Colquitt, Lauren et al. (2018) Personalized expression of bitter 'taste' receptors in human skin. PLoS One 13:e0205322
Zheng, Qi; Bartow-McKenney, Casey; Meisel, Jacquelyn S et al. (2018) HmmUFOtu: An HMM and phylogenetic placement based ultra-fast taxonomic assignment and OTU picking tool for microbiome amplicon sequencing studies. Genome Biol 19:82
Ellebrecht, Christoph T; Mukherjee, Eric M; Zheng, Qi et al. (2018) Autoreactive IgG and IgA B Cells Evolve through Distinct Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris. Cell Rep 24:2370-2380
Stewart, C L; Cornejo, C M; Wanat, K A et al. (2018) The immune reconstitution of the skin following sex-mismatched allogeneic haematopoietic stem cell transplant: a prospective case series utilizing fluorescence in situ hybridization and immunohistochemistry. Br J Dermatol 178:e55-e56
Nishiguchi, Mailyn A; Spencer, Casey A; Leung, Denis H et al. (2018) Aging Suppresses Skin-Derived Circulating SDF1 to Promote Full-Thickness Tissue Regeneration. Cell Rep 24:3383-3392.e5
Lin-Shiao, Enrique; Lan, Yemin; Coradin, Mariel et al. (2018) KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis. Genes Dev 32:181-193
Liu, Wei; Krump, Nathan A; MacDonald, Margo et al. (2018) Merkel Cell Polyomavirus Infection of Animal Dermal Fibroblasts. J Virol 92:
Meisel, Jacquelyn S; Sfyroera, Georgia; Bartow-McKenney, Casey et al. (2018) Commensal microbiota modulate gene expression in the skin. Microbiome 6:20
Wing, Anna; Fajardo, Carlos Alberto; Posey Jr, Avery D et al. (2018) Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Cancer Immunol Res 6:605-616
Natale, Christopher A; Li, Jinyang; Zhang, Junqian et al. (2018) Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. Elife 7:

Showing the most recent 10 out of 37 publications